Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
2006a;283(1-2):3945
Paik D, Yao L, Zhang Y, Bae S, DAgostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco J, Bisanz JE, Rakowski CK, Vlamakis H, Xavier RJ, Turnbaugh PJ, Longman RS, Krout MR, Clish CB, Rastinejad F, Huttenhower C, Huh JR, Devlin AS (2022) Human gut bacteria produce TH17-modulating bile acid metabolites
These entrants are leveraging strengths in peptide synthesis, low-cost biologics manufacturing, and regulatory agility to shorten development cycles and undercut price points, potentially halving or even reducing cost to one-tenth of current therapy levels
However, GLP-1RAs have only been shown to reduce albuminuria, and their ability to reduce progression to ESRD remains to be elucidated
The common denominator between keto and GLP-1 agonists is blood sugar control[ii]
